Pasithea Therapeutics

Pasithea Therapeutics Current Liabilities

The Current Liabilities of Pasithea Therapeutics (KTTA) as of Nov 21, 2026 is 4.97 M USD. In the previous year, Current Liabilities was 2.24 M USD — a change of 122.08% (higher).

Current Liabilities

4.97 MUSD

YoY

122.08%

Last updated:

Current Liabilities of Pasithea Therapeutics is 2025 4.97 M USD. Current Liabilities of Pasithea Therapeutics was 2024 2.24 M USD. It decreases by 122.08% higher compared to the previous year.

The Pasithea Therapeutics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2020
13,206.00 USD
Jan 1, 2021
894,560.00 USD
Jan 1, 2022
2.14 M USD
Jan 1, 2024
2.24 M USD
Jan 1, 2025
4.97 M USD
The Pasithea Therapeutics Current Liabilities history
YEARCurrent LiabilitiesYoY
4.97 MUSD+122.08%
2.24 MUSD+4.63%
2.14 MUSD+139.29%
894,560.00USD+6,673.89%
13,206.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pasithea Therapeutics Stock analysis

What does Pasithea Therapeutics do? Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics. Pasithea Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pasithea Therapeutics stock

Current Liabilities of Pasithea Therapeutics is 4.97 M USD in 2025.

Current Liabilities of Pasithea Therapeutics changed from 2.24 M USD to 4.97 M USD, representing a 122.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Pasithea Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Pasithea Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Pasithea Therapeutics

All Key Metrics — Pasithea Therapeutics